|
Apr 17
|
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
|
|
Apr 5
|
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Apr 3
|
89bio Inc CEO Rohan Palekar Sells 52,718 Shares
|
|
Mar 27
|
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
|
|
Mar 18
|
Ozempic Can’t Do It All—A Potential New Blockbuster Is a Reminder of That
|
|
Mar 13
|
13 Best Biotech Stocks To Buy Under $20
|
|
Mar 12
|
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
|
|
Mar 8
|
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 5
|
89bio to Participate in the Leerink Partners Global Biopharma Conference
|
|
Mar 5
|
Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study
|
|
Mar 5
|
Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%: Here's is How to Trade
|
|
Mar 5
|
89BIO (ETNB) Just Overtook the 200-Day Moving Average
|
|
Mar 4
|
Why Akero Rocketed — And Pulled Rival 89bio Higher — On Results In Liver Disease Treatment
|
|
Mar 4
|
Data Suggests Makers of Fatty Liver Treatments Won’t Be Displaced by Obesity Drugs
|
|
Jan 10
|
Does 89BIO (ETNB) Have the Potential to Rally 168.77% as Wall Street Analysts Expect?
|
|
Dec 7
|
89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants
|
|
Dec 6
|
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
|
|
Dec 4
|
89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024
|
|
Nov 27
|
89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)
|
|
Sep 21
|
89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)
|